Sumit Sheoran | Cancer Biomarkers | Innovative Research Award

Innovative Research Award

Sumit Sheoran
Babasaheb Bhimrao Ambedkar University

                          Sumit Sheoran
Affiliation Babasaheb Bhimrao Ambedkar University
Country India
Scopus ID 57755350400
Documents 10
Citations 188
h-index 5
Subject Area Cancer Biomarkers
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0002-2519-8506

The Innovative Research Award recognizes emerging and impactful scientific contributions in oncology-related research. Sumit Sheoran has established a scholarly profile in cancer biomarker investigations, with publications indexed in major academic databases and measurable citation impact. His research activities demonstrate engagement with molecular oncology, biomarker discovery, and translational biomedical science, contributing to the broader understanding of cancer diagnosis and therapeutic development.[1][2]

Abstract

Sumit Sheoran is a researcher associated with Babasaheb Bhimrao Ambedkar University whose academic activities focus on cancer biomarkers and related biomedical investigations. His scholarly record includes peer-reviewed publications indexed in Scopus, demonstrating contributions to oncology-oriented research and translational scientific studies. With documented citation performance and a growing research profile, his work supports ongoing efforts to improve understanding of disease mechanisms, biomarker identification, and evidence-based clinical applications. The combination of publication output, citation recognition, and engagement in cancer research highlights a profile aligned with contemporary priorities in oncology and biomedical innovation.[1][2]

Keywords

  • Cancer Biomarkers
  • Oncology Research
  • Translational Medicine
  • Molecular Diagnostics
  • Biomedical Research
  • Cancer Biology

Introduction

Cancer biomarker research plays a central role in advancing precision medicine, early diagnosis, prognostic assessment, and therapeutic monitoring. Sumit Sheoran’s academic work is positioned within this evolving field, emphasizing scientific inquiry that contributes to the understanding of cancer-related biological processes. Through peer-reviewed publications and scholarly engagement, his research supports evidence generation relevant to contemporary oncology challenges and emerging diagnostic strategies.[1]

Research Profile

Affiliated with Babasaheb Bhimrao Ambedkar University, Sumit Sheoran maintains a documented scholarly presence through Scopus, ORCID, Google Scholar, and ResearchGate profiles. His publication record includes ten indexed documents with citation activity reflecting academic visibility. The research profile demonstrates continued participation in oncology-related investigations and interdisciplinary biomedical research initiatives.[1][2]

Research Contributions

The research contributions of Sumit Sheoran are associated with cancer biomarker discovery, molecular characterization, and biomedical investigations relevant to oncology. His scholarly outputs contribute to scientific discussions concerning disease detection, biomarker validation, and translational research applications. These efforts support broader objectives aimed at improving diagnostic accuracy and strengthening evidence-based cancer research frameworks.[1]

Publications

The researcher has produced ten Scopus-indexed publications addressing themes related to cancer biomarkers and biomedical sciences. These publications have accumulated citation recognition within the scholarly community and contribute to the dissemination of scientific knowledge. Publication activity demonstrates sustained participation in peer-reviewed research and academic communication within relevant scientific disciplines.[1]

Research Impact

Research impact is reflected through documented citation metrics, publication visibility, and engagement within oncology research networks. With 188 citations and an h-index of 5, the available bibliometric indicators suggest that the research outputs have contributed to ongoing scientific discourse. Such indicators provide evidence of academic relevance and scholarly recognition.[3]

Award Suitability

The Innovative Research Award emphasizes scientific originality, measurable research outcomes, and disciplinary relevance. Sumit Sheoran’s documented publication record, citation performance, and specialization in cancer biomarkers align with these evaluation dimensions. His contributions to oncology-focused research provide a reasonable basis for consideration within an international research recognition framework.[1][4]

Conclusion

Sumit Sheoran has developed an emerging research profile characterized by contributions to cancer biomarker studies, peer-reviewed publications, and measurable citation impact. His scholarly activities support the advancement of oncology research and demonstrate alignment with the objectives of international scientific recognition programs that value innovation, research quality, and academic engagement.[1][2]

References

  1. Elsevier. (n.d.). Scopus author details: Sumit Sheoran, Author ID 57755350400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57755350400
  2. ORCID. (n.d.). Sumit Sheoran: ORCID record 0000-0002-2519-8506.
    https://orcid.org/0000-0002-2519-8506
  3. Google Scholar. (n.d.). Scholar profile of Sumit Sheoran.
    https://scholar.google.com/citations?hl=en&user=sz3r5rQAAAAJ
  4. ResearchGate. (n.d.). Sumit Sheoran research profile and scholarly outputs.
    https://www.researchgate.net/profile/Sumit-Sheoran-8

Ping Dai | Cancer Therapy | Best Researcher Award

Dr. Ping Dai | Cancer Therapy | Best Researcher Award

Tongji University | China

AUTHOR PROFILE

SCOPUS ID

🏥DR. PING DAI: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Ping Dai’s journey in medicine began with a Diploma of Higher Education in Clinical Medicine from Harbin University, followed by a Bachelor’s degree at Qiqihar Medical University. She excelled further with an Outstanding Master’s Degree in Oncology from Shihezi University, and culminated her academic path with a Doctorate in Molecular Radiation Oncology (Dr. Med, Magna Cum Laude) from the prestigious Heidelberg University in Germany—underscoring a profound commitment to academic excellence and clinical innovation.

🩺PROFESSIONAL ENDEAVORS

With over a decade of clinical and research experience, Dr. Dai currently serves as Assistant Director at the Shanghai Fourth People’s Hospital Affiliated to Tongji University. Her career spans multiple critical roles—oncologist, clinical researcher, and international doctoral candidate at the German Cancer Research Centre (DKFZ)—fusing global perspectives with localized healthcare innovation.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BIOMARKERS  IN CANCER THERAPY

Dr. Dai’s research centers on radiation oncology, immunotherapy-related thyroid dysfunction, and tumor treating fields (TTFields). Notably, her recent studies explore PD-1/PD-L1 inhibitor-induced thyroid dysfunction as a biomarker for efficacy in advanced lung cancer therapy, published in BMC Cancer and Heliyon. She also leads groundbreaking simulation research on electrodynamic tumor interactions, merging clinical oncology with bioengineering insight.

🌍IMPACT AND INFLUENCE

Dr. Dai’s cross-continental experience—from China to Germany—bridges Eastern and Western oncology practices. Her insights contribute to both clinical protocol improvements and space-radiation biology, collaborating with institutions such as the European Space Agency and Heidelberg Ion Beam Therapy Center. She plays a vital role in shaping translational cancer science and space medicine.

🏆ACADEMIC CITES, ACCOLADES AND RECOGNITION

  • Lead or corresponding author in high-impact journals: Cancer Letters (IF 9.7), APL Bioengineering (IF 6.6), and Frontiers in Oncology.

  • Honored with Outstanding Master’s Graduate award.

  • Latin honors “Magna Cum Laude” for doctoral studies in Germany.

  • Recognized as equal-first author and corresponding author in multiple prestigious publications.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Dai is establishing a legacy of translational research at the intersection of radiation therapy, immunology, and biomarker discovery. Her future pursuits aim to:

  • Advance predictive markers for immunotherapy outcomes.

  • Explore MSC-based interventions against radiation-induced myelotoxicity.

  • Lead multinational clinical collaborations in cancer therapy and space radiation countermeasures.

🧬CONCLUSION

Dr. Ping Dai is an emerging force in molecular oncology and translational medicine. With a rich academic foundation, strong clinical acumen, and a forward-thinking research vision, she is contributing impactful solutions to global oncology and radiobiology challenges.

📊🔬NOTABLE PUBLICATION:

Thyroid dysfunction as a predictor of PD-1/PD-L1 inhibitor efficacy in advanced lung cancer

Authors: Yanling Wang, Xiaoping Ma, Jia Ma, Jing Li, Zhiyi Lin, Wei Gao, Ping Gong, Ping Dai
Journal: BMC Cancer
Year: 2025

Comprehensive Simulations of Intracellular Electric Fields during Exposure to Tumor Treating Fields (TTFields)

Authors: Kaida Liu, Ping Dai, Zirong Liu, Haohan Fang, Xing Li, Wei Gao
Journal: Frontiers in Oncology
Year: 2025 (Accepted)

Electrodynamic Interaction between Tumor Treating Fields and Microtubule Electrophysiological Activities

Authors: Xing Li, Kaida Liu, Haohan Fang, Zirong Liu, Yuchen Tang, Ping Dai
Journal: APL Bioengineering
Year: 2024

A theoretical study on evaluating brain tumor changes in tumor treating fields therapy by impedance detection

Authors: Xing Li, Kaida Liu, Haohan Fang, Rongzi Liu, Wei Gao, Ping Dai
Journal: Frontiers in Oncology
Year: 2024